Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
done now gimme ten
gimme five
The Transaction
The merger agreement provides that Bank of Granite shareholders will receive 3.375 shares of FNB's common stock in exchange for each share of Bank of Granite common stock they own immediately prior to completion of the merger.
good timing
this is tricky ...
please show me this schedule...
Section 5.2 Ownership of Non-Debtor Subsidiaries.
(a) Except as otherwise indicated on Schedule 5.2(a), all of the outstanding
capital stock or other equity interests of each Non-Debtor Subsidiary are owned, directly or
indirectly, by the owner reflected on Schedule 5.2(a), free and clear of any and all Liens, other
than (i) restrictions on transfer that may be imposed by federal or state securities Laws, (ii) Liens
that arise out of any actions taken by or on behalf of Purchaser or its Affiliates, or (iii) Permitted
Liens. All equity interests of each Non-Debtor Subsidiary have been validly issued and are fully
paid, nonassessable and were not issued in violation of any purchase or call option, right of first
refusal, subscription right, preemptive right or any similar rights.
(b)
“Non-Debtor Subsidiaries” means the foreign subsidiaries of Sellers that are listed on
Schedule 1.1(d), provided that Purchaser, in its sole discretion, at any time and from time to time
prior to the Closing, shall be entitled to modify such schedule to (i) remove any one or more of
the subsidiaries of Sellers listed thereon and/or (ii) add any one or more of the Subsidiaries of
Sellers that are not Debtors. For the avoidance of doubt, the representations and warranties set
US_ACTIVE:\43685878\09\27258.0004 9
forth in Article V with respect to the Non-Debtor Subsidiaries are being made by Sellers solely
with respect to the Non-Debtor Subsidiaries that are listed on Schedule 1.1(e) as of the date
hereof.
and now....
extension for what!!??
why are you so busy?
this stock is ch. 11!
enjoy the up and downs due to rumours
1-15-28-35
enjoy!
where is the link?
are you sure...?
hope you have five fingers each left and right!!
please give me a link.
would you buy this stock @ .25
sometimes it`s really hard to recognize an asset
1. strike is in!
time to cover @ 2,5 dollares.
yep, yep, yep.
try it on monday )
16/17 for sure. 12/13 was tested last two days, but MM hold this down for some reason! they called it the play of resistance!!
icahn = $$$$$
looks like a nice upgapper
is SAR down trend yet broken or not!? is this similar to your post
doji is not a sign for failed TA... need to improve tomorrow how it works out
Genta Receives Scientific Advice from European Medicines Agency Supporting Randomized Phase 3 Trial of Tesetaxel in Patients with Advanced Gastric Cancer
Monday , November 01, 2010 08:05ET
BERKELEY HEIGHTS, N.J.--(BUSINESS WIRE)-- Genta Incorporated (OTCBB: GNTA.OB) today announced that the Company has received Scientific Advice from the European Medicines Agency (EMA) on the Company's clinical development plan for tesetaxel in patients with advanced gastric cancer, which includes a pivotal, randomized, controlled, Phase 3 trial. The EMA's written advice is supportive of Genta's proposed Phase 3 trial in patients with advanced gastric cancer whose disease has progressed on 1st-line chemotherapy. The EMA issued the advice following its established consultative review process, which provides development clarity toward a potential regulatory submission for marketing approval.
Genta is currently discussing plans for this Phase 3 trial with other regulatory agencies, including the U.S. Food and Drug Administration (FDA). Further information about the trial will be provided upon completion of the Company's ongoing regulatory discussions.
Tesetaxel has been designated an Orphan Drug by both FDA and EMA for treatment of patients with advanced gastric cancer. FDA has also granted Fast Track designation for tesetaxel in patients with advanced gastric cancer.
About Scientific Advice
Scientific Advice is a procedure offered by the EMA to stakeholders for clarification of questions arising during development of medicinal products. The scope of Scientific Advice is limited to scientific issues, i.e. to quality, non-clinical, and clinical aspects of the concerned medicinal product not yet unequivocally covered by published scientific guidelines. Scientific Advice focuses on development strategies rather than pre-evaluation of data to support a Marketing Authorization Application. Scientific Advice is legally non-binding and is based on current scientific knowledge that may be subject to future changes.
About Tesetaxel
Taxanes (including paclitaxel and docetaxel) are the most widely used chemotherapy drug class in cancer medicine. However, these agents are associated with serious safety issues, particularly hypersensitivity reactions related to intravenous infusions that are occasionally fatal and that require premedication and careful observation. Other prominent side-effects of this drug class include myelosuppression (low blood counts) and peripheral neuropathy (disabling nerve damage).
Tesetaxel is a novel taxane that is administered by mouth as a capsule. The drug was developed with a goal of maintaining antitumor activity while eliminating infusion reactions, reducing neuropathy, and increasing patient convenience. The oral route also enables the development of novel schedules that may expand dosing options when tesetaxel is combined with other anticancer drugs (such as "all oral" chemotherapy programs). In experimental models, tesetaxel has demonstrated high activity against tumors that are resistant to paclitaxel and docetaxel.
About Genta
take a mirror and try to cover under 8 dollars
so you changed your mind.. congrats!
this wasn`t a good call LOL
Happy Halloween!
I got some info from a VERY GOOD SOURCE last night who says that the way it looks now, the union will be voting "no" by a 70-30 percentage.
shame and shame over you. please never post again here!!!!!!!!!!
look on fridays chart... the shorts will get it`s D-day.. for sure...
once again...shame on you!!!!!
thanks for your VERY GOOD SOURCE... i hope it helps LOL!!
thanks ed... please update the ibox over the weekend with this great news. do you think we get some upgrades from analysts?
see you on monday and watch
time to recover from here i don`t know why but this puppy has tanked heavily and a bounce is overdue so i decided to buy some gnta only to my TA. please don`t follow my TA because you can lost a lot of money or not...!?
some people will miss the first 50 % due to TA.
truth will come out... may be we`ll see some bio-bernie!!!
should i buy neom.... no and no... i like arna!!
why so??
tomorrow up-popper?
how much?
50 or 100 per cent.. thats the question now!?
shaka shaka ... new symbol new luck...
Open Gaps
Direction Date range
up Sept-09-2010 0.035 to 0.88
down Oct-11-2010 0.3 to 0.235
what about the "fresh" gap`s...?
close this up from 0.001 sounds strange...very strange.
the robberies self-discription...
About Morgan Keegan & Company Inc.
Morgan Keegan & Company Inc., one of the nation’s largest regional full-service brokerage and investment banking firms, is the securities brokerage arm of Regions Financial Corporation (NYSE: RF). Headquartered in Memphis, Tenn., Morgan Keegan serves individual and institutional investors in over 300 offices in 19 states. Additional information about Morgan Keegan can be found here.